Jane E Roberts1, Bridgette L Tonnsen2, Lindsay M McCary3, Amy L Ford4, Robert N Golden5, Donald B Bailey6. 1. Department of Psychology, University of South Carolina, Columbia, South Carolina. Electronic address: Jane.Roberts@sc.edu. 2. Department of Psychology, Purdue University, West Lafayette, Indiana. 3. Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin. 4. Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina. 5. School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. 6. RTI International, Research Triangle Park, North Carolina.
Abstract
BACKGROUND: Although the FMR1 premutation is associated with elevated prevalence of psychiatric disorders, the longitudinal course of symptoms has not been established. The present study followed a sample of women with the FMR1 premutation to characterize the incidence, stability, and predictors of mood and anxiety disorders across a 3-year period. METHODS: Participants included 83 women with the FMR1 premutation (mean age = 38.35) who completed the Structured Clinical Interview for DSM-IV Axis I Disorders at two time points, 3 years apart. Additional information was obtained regarding demographic, child, and biomedical (e.g., medication, menopause, CGG repeats) factors. RESULTS: We found increased prevalence of major depressive disorder (MDD) and anxiety disorders over time, with adverse outcomes predicted by complex interactions among biological, behavioral, and environmental risk factors. Lifetime MDD increased from 46% to 54% and lifetime anxiety disorders increased from 28% to 35%. Midrange CGG repeats, elevated child problem behaviors, and divorced marital status conveyed elevated risk for psychiatric diagnoses. Primary ovarian insufficiency was highly prevalent (41%) but did not account for elevated rates of psychiatric diagnoses. Medication use was highly reported (41%), particularly in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the most commonly used medication across diagnostic groups. CONCLUSIONS: The elevated prevalence of depression and anxiety in women with the FMR1 premutation is a clear and pressing concern given the frequent occurrence of the FMR1 premutation in the general community and the adverse outcomes-at both individual and systems levels-associated with psychiatric disorders in this population.
BACKGROUND: Although the FMR1 premutation is associated with elevated prevalence of psychiatric disorders, the longitudinal course of symptoms has not been established. The present study followed a sample of women with the FMR1 premutation to characterize the incidence, stability, and predictors of mood and anxiety disorders across a 3-year period. METHODS:Participants included 83 women with the FMR1 premutation (mean age = 38.35) who completed the Structured Clinical Interview for DSM-IV Axis I Disorders at two time points, 3 years apart. Additional information was obtained regarding demographic, child, and biomedical (e.g., medication, menopause, CGG repeats) factors. RESULTS: We found increased prevalence of major depressive disorder (MDD) and anxiety disorders over time, with adverse outcomes predicted by complex interactions among biological, behavioral, and environmental risk factors. Lifetime MDD increased from 46% to 54% and lifetime anxiety disorders increased from 28% to 35%. Midrange CGG repeats, elevated child problem behaviors, and divorced marital status conveyed elevated risk for psychiatric diagnoses. Primary ovarian insufficiency was highly prevalent (41%) but did not account for elevated rates of psychiatric diagnoses. Medication use was highly reported (41%), particularly in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the most commonly used medication across diagnostic groups. CONCLUSIONS: The elevated prevalence of depression and anxiety in women with the FMR1 premutation is a clear and pressing concern given the frequent occurrence of the FMR1 premutation in the general community and the adverse outcomes-at both individual and systems levels-associated with psychiatric disorders in this population.
Authors: D J Allingham-Hawkins; R Babul-Hirji; D Chitayat; J J Holden; K T Yang; C Lee; R Hudson; H Gorwill; S L Nolin; A Glicksman; E C Jenkins; W T Brown; P N Howard-Peebles; C Becchi; E Cummings; L Fallon; S Seitz; S H Black; A M Vianna-Morgante; S S Costa; P A Otto; R C Mingroni-Netto; A Murray; J Webb; F Vieri Journal: Am J Med Genet Date: 1999-04-02
Authors: Ave M Lachiewicz; Deborah V Dawson; Gail A Spiridigliozzi; Allyn McConkie-Rosell Journal: Am J Med Genet A Date: 2006-04-01 Impact factor: 2.802
Authors: Kim M Cornish; Lexin Li; Cary S Kogan; Sebastien Jacquemont; Jeremy Turk; Ann Dalton; Randi J Hagerman; Paul J Hagerman Journal: Cortex Date: 2007-12-23 Impact factor: 4.027
Authors: Sébastien Jacquemont; Randi J Hagerman; Maureen A Leehey; Deborah A Hall; Richard A Levine; James A Brunberg; Lin Zhang; Tristan Jardini; Louise W Gane; Susan W Harris; Kristin Herman; James Grigsby; Claudia M Greco; Elizabeth Berry-Kravis; Flora Tassone; Paul J Hagerman Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: P Franke; M Leboyer; M Gänsicke; O Weiffenbach; V Biancalana; P Cornillet-Lefebre; M F Croquette; U Froster; S G Schwab; F Poustka; M Hautzinger; W Maier Journal: Psychiatry Res Date: 1998-08-17 Impact factor: 3.222
Authors: Feras M Hantash; Dana M Goos; Beryl Crossley; Ben Anderson; Ke Zhang; Weimin Sun; Charles M Strom Journal: Genet Med Date: 2011-01 Impact factor: 8.822